Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
Solange Peters(University Hospital of Lausanne), Egbert F. Smit(Dutch Cancer Society), Daniel Rauch(Washington University in St. Louis), Óscar Juan(Hospital Universitari i Politècnic La Fe), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico), Rolf A. Stahel(International Breast Cancer Study Group), Robbert van Heemst(Deventer Ziekenhuis), Bartomeu Massutí(Universitat de Miguel Hernández d'Elx), P.M. van den Berg(Maasstad Ziekenhuis), Amelia Insa(Hospital Clínico Universitario de Valencia), Yojena Chittazhathu Kurian Kuruvilla, Manuel Cobo(Instituto de Investigación Biomédica de Málaga), Peter Meldgaard(Aarhus University Hospital), Ramón Palmero(Institut Català d'Oncologia), Alessandra Curioni‐Fontecedro(University of Fribourg), Vanesa Gregorc(IRCCS Ospedale San Raffaele), Zoi Tsourti(Frontier Science Foundation-Hellas), Bonne Biesma(Heidelberg University), Yvonne Summers(The Christie NHS Foundation Trust), Sergio Peralta(Hospital Universitari Sant Joan de Reus), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Remge M. Pieterman, Harry J.M. Groen(University Medical Center Groningen), Arjen M.J. van Henten(Radboud University Nijmegen), Michael Mark(Kantonsspital Graubünden), Sander de Hosson(Wilhelmina Children's Hospital), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Ricardo Collado(Hospital San Pedro de Alcántara), Adriana Gasca-Ruchti, Marie Kassapian(Frontier Science Foundation-Hellas), Christoph Zielinski(Vienna General Hospital), Urania Dafni(Frontier Science Foundation-Hellas), Anne M. Horgan(Queen Elizabeth Hospital Birmingham), Sinéad Cuffe(Cancer Trials Ireland), Ana López(Hospital Universitario Severo Ochoa), István Láng(National Institute of Oncology), Linda Coate(University Health Network), José Carlos Villa Guzmán(Hospital General Universitario de Ciudad Real), Silvia Novello(University of Turin), Santiago Ponce Aix(Research Institute Hospital 12 de Octubre), Thierry Berghmans(Institut Jules Bordet)
Cited by 22
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k